Stocks Under Review:Portland General Electric Company(NYSE:POR), Portola Pharmaceuticals Inc (NASDAQ:PTLA), VMware, Inc. (NYSE:VMW)

On Friday, Shares of Portland General Electric Company (NYSE:POR), subtract -0.48% and closed at $41.90 in the last trading session. The last trading range of the stock ranges between $41.79 and $42.59. Portland General Electric Company, an integrated electric utility company, engages in the generation, wholesale purchase, transmission, distribution, and retail sale of electricity in the state of Oregon. The company operates six thermal plants; seven hydroelectric plants; and two wind farms, counting the Biglow Canyon wind farm and the Tucannon River wind farm. It has about 26,544 circuit miles of primary and secondary distribution lines. As of December 31, 2015, it owned an electric transmission system consisting of 1,239 circuit miles, counting 286 circuit miles of 500 kilovolt line, 402 circuit miles of 230 kilovolt line, and 551 miles of 115 kilovolt line.

Portola Pharmaceuticals Inc (NASDAQ:PTLA), jumped 1.50% and closed at $18.25 in the last trading session. The last trading range of the stock ranges between $17.41 and $18.53. The company’s Market capitalization is $1.05 Billion with the total Outstanding Shares of 56.54 million. Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral, once-daily Factor Xa inhibitor, which is in Phase III clinical trial for treating venous thromboembolism prophylaxis in acute medically ill patients in-hospital and post discharge; and Andexanet alfa, a recombinant protein that is designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor. The company is also developing Cerdulatinib, which is in Phase I/IIa proof-of-concept study, an orally available kinase inhibitor that inhibits spleen tyrosine kinase (Syk) and janus kinases enzymes, which regulate signaling pathways, in addition to for hematologic, or blood, cancers, and inflammatory disorders. In addition, it is involved in the development of PRT2607, a selective Syk inhibitor.

VMware, Inc. (NYSE:VMW), dropped -0.49% and closed at $76.44 in the last trading session. The last trading range of the stock ranges between $76.14 and $76.89.The company stock’s 52-week range is $43.25 – $79.15. VMware, Inc. (VMW), a global leader in cloud infrastructure and business mobility, recently declared that it has been positioned as a leader in the “IDC MarketScape: Worldwide Virtual Client Computing Software 2016 Vendor Assessment (doc # US40700016, November 2016).” The report evaluated 8 vendors based on criteria that spans across strategies and capabilities. VMware was recognized for the second successive year for having the most complete mix of business and solution strategies and capabilities for delivering virtual desktops and applications through its VMware Horizon® portfolio of solutions and services that includes VMware Horizon® 7, Horizon Air™, Horizon FLEX™ and VMware App Volumes™.

According to the IDC MarketScape report, “In the reference survey we found that the top 2 reasons customers stated for choosing VMware’s VCC solutions was that its pricing/offer was competitive and the perception that its products had better capabilities. As to reference perceptions of the company as contrast to its peers, VMware generally rated higher than average in all 9 areas.”

Leave a Reply

Your email address will not be published. Required fields are marked *